(this["webpackJsonpumms-app"]=this["webpackJsonpumms-app"]||[]).push([[0],{48:function(e,n,t){},49:function(e,n,t){},57:function(e){e.exports=JSON.parse('{"drugs":[{"id":"1","name":"Yescarta\xae (Axicabtagene Ciloleucel)","gradeTypes":[{"name":"CRS Toxicity","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":"Anti IL-6 and corticosteroids:\\n If in Grade 1 for <72h \u2013 none\\n\\n No improvement after 72h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr\\n Repeat every 4-6 hours as needed\\n +\\n Dexamethasone 10 mg x 1  \\n\\n Consider levetiracetam for seizure prophylaxis.\\n& No improvement after 24h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr. \\n\\n If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. \\n\\n If improving, discontinue tocilizumab.\\n& No improvement after 72h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr\\n\\n If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. \\n If improving, discontinue tocilizumab.\\n +\\n Dexamethasone 10 mg x 1\\n","followup":null},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Anti- IL-6 and corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n +\\n Dexamethasone 10 mg intravenously once daily. If improving, manage as Grade 1  and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade 3.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Anti IL-6 and corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n +\\n Dexamethasone 10 mg intravenously three times a day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as Grade 4.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or lifethreatening CRS, consider intensive-care supportive therapy\\n ","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\nRequirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Anti IL-6 and Corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n +\\n Methylprednisolone 1000 mg intravenously once per day for 3 days. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider methylprednisolone 1000 mg 2-3 times a day or alternate therapy.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or lifethreatening CRS, consider intensive-care supportive therapy\\n ","followup":null}]},{"name":"NeuroToxicity","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\nConfusion - mild disorientation \\nEncephalopathy - mild limiting of ADLs \\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab per  Grade 1 CRS. In addition, administer one dose of dexamethasone 10 mg intravenously. If not improving after 2 days, repeat dexamethasone 10 mg intravenously.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer one dose of dexamethasone 10 mg intravenously.\\n If not improving after 2 days, repeat \\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities (Table 2). Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer dexamethasone 10 mg intravenously four times a day. If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade below.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer dexamethasone 10 mg intravenously four times a day. If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade below.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\nConfusion - severe disorientation \\nEncephalopathy - limiting self-care ADLs \\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer methylprednisolone 1000 mg intravenously once daily. If improving, manage as appropriate grade 2 and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, manage as Grade 4. \\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer methylprednisolone 1000 mg intravenously once daily. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, manage as Grade 4.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 4","description":"Life threatening consequences \\nUrgent intervention indicated\\nRequirement for mechanical ventilation \\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer methylprednisolone 1000 mg intravenously twice per day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer methylprednisolone 1000 mg intravenously twice per day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}}]}]},{"id":"2","name":"matthew\'s drug","gradeTypes":[{"name":"crs","grades":[{"name":"grade1","description":"1","response":"1"},{"name":"grade2","description":"1","response":"1"},{"name":"grade3","description":"1","response":"1"},{"name":"grade4","description":"1","response":"1"}]},{"name":"neurotox","grades":[{"name":"grade1","description":"1","response":"1"},{"name":"grade2","description":"1","response":"1"},{"name":"grade3","description":"1","response":"1"},{"name":"grade4","description":"1","response":"1"}]}]}]}')},59:function(e,n,t){"use strict";t.r(n);var i,o,r,a,s,c,d,m=t(0),p=t.n(m),l=t(20),u=t.n(l),g=(t(48),t(19)),h=(t(49),t(67)),x=t.p+"static/media/logo.412a2035.jpg",f=t(64),b=t(69),j=t(5),y=t(6),v=t(61),O=t(62),C=t(63),I=y.a.img(i||(i=Object(j.a)(["\n    width: 90%;\n    height: 100%;\n    // margin-top: 5%;\n"]))),z=Object(y.a)(v.a)(o||(o=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n"]))),w=Object(y.a)(v.a)(r||(r=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    position:fixed;\n    left:0;\n    bottom:0;\n    right:0;\n"]))),S=Object(y.a)(O.a)(a||(a=Object(j.a)(["\n    font-size: 300%;\n"]))),A=Object(y.a)(b.a)(s||(s=Object(j.a)(["\n    // display: flex;\n    flex-direction: row;\n    // background-color: red;\n    align-items: center;\n    // border: 2px solid rgba(0,0,0,.125);\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"]))),G=Object(y.a)(C.a)(c||(c=Object(j.a)(["\n    margin-right: 1%;\n"]))),R=Object(y.a)(v.a)(d||(d=Object(j.a)(["\n    justify-content: center;\n    margin-top: 9%;\n"]))),k=t(4),L=t(15),T=function(e,n){var t=null;if(n===[null])return null;var i,o=Object(L.a)(n);try{for(o.s();!(i=o.n()).done;){var r,a=i.value,s=Object(L.a)(e);try{for(s.s();!(r=s.n()).done;){var c=r.value;if(c.name===a){e=c,t=c;break}}}catch(d){s.e(d)}finally{s.f()}}}catch(d){o.e(d)}finally{o.f()}return t},F=function(e,n){e.push("".concat(window.location.pathname).concat(n,"/"))},q=t(1);var D,M,N,P,B,Y,E,J=function(){var e=Object(k.f)();return Object(q.jsxs)(q.Fragment,{children:[Object(q.jsx)(z,{children:Object(q.jsx)(I,{src:x,alt:"logo"})}),Object(q.jsx)(R,{children:Object(q.jsxs)(f.a,{children:[Object(q.jsxs)(A,{children:[Object(q.jsx)(S,{}),Object(q.jsx)(b.a.Body,{children:Object(q.jsx)(b.a.Title,{children:"Toxicity Grading"})})]}),Object(q.jsxs)(A,{children:[Object(q.jsx)(S,{}),Object(q.jsx)("div",{onClick:function(){return F(e,"toxicitymanagement")},children:Object(q.jsx)(b.a.Body,{children:Object(q.jsx)(b.a.Title,{children:"Toxicity Management"})})})]})]})}),Object(q.jsxs)(w,{children:[Object(q.jsx)(G,{}),Object(q.jsx)("span",{children:"About Us"})]})]})},H=(y.a.img(D||(D=Object(j.a)(["\n    width: 90%;\n    height: 100%;\n    // margin-top: 5%;\n"]))),Object(y.a)(v.a)(M||(M=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n"]))),Object(y.a)(v.a)(N||(N=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    position:fixed;\n    left:0;\n    bottom:0;\n    right:0;\n"]))),Object(y.a)(O.a)(P||(P=Object(j.a)(["\n    font-size: 300%;\n"]))),Object(y.a)(b.a)(B||(B=Object(j.a)(["\n    // display: flex;\n    flex-direction: row;\n    // background-color: red;\n    align-items: center;\n    // border: 2px solid rgba(0,0,0,.125);\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"])))),K=(Object(y.a)(C.a)(Y||(Y=Object(j.a)(["\n    margin-right: 1%;\n"]))),Object(y.a)(v.a)(E||(E=Object(j.a)(["\n    justify-content: center;\n    margin-top: 9%;\n"]))));var U=function(e){var n,t=Object(k.f)(),i=e.data.drugs,o=[],r=Object(L.a)(i);try{var a=function(){var e=n.value;o.push(Object(q.jsx)("div",{onClick:function(){return F(t,e.name)},children:Object(q.jsx)(H,{children:Object(q.jsx)(b.a.Body,{children:Object(q.jsx)(b.a.Title,{children:e.name})})})},"".concat(e.name," card")))};for(r.s();!(n=r.n()).done;)a()}catch(s){r.e(s)}finally{r.f()}return Object(q.jsx)(q.Fragment,{children:Object(q.jsx)(K,{children:Object(q.jsx)(f.a,{children:o})})})},V=t(24);var Q,W,X,Z,$,_,ee,ne,te,ie,oe,re=function(e){var n=e.data,t=Object(k.g)().drugtype,i=T(n.drugs,[t]).gradeTypes,o=Object(k.f)();return Object(q.jsx)(q.Fragment,{children:Object(q.jsx)(K,{children:Object(q.jsxs)(f.a,{children:[Object(q.jsx)("div",{onClick:function(){return F(o,i[0].name)},children:Object(q.jsx)(H,{children:Object(q.jsx)(b.a.Body,{children:Object(q.jsx)(b.a.Title,{children:i[0].name})})})}),Object(q.jsx)("div",{onClick:function(){return F(o,i[1].name)},children:Object(q.jsx)(H,{children:Object(q.jsx)(b.a.Body,{children:Object(q.jsx)(b.a.Title,{children:i[1].name})})})})]})})})},ae=t(35),se=t(66),ce=t(68),de=t(70),me=t(65),pe=(y.a.img(Q||(Q=Object(j.a)(["\n    width: 90%;\n    height: 100%;\n    // margin-top: 5%;\n"]))),Object(y.a)(v.a)(W||(W=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n"]))),Object(y.a)(v.a)(X||(X=Object(j.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    position:fixed;\n    left:0;\n    bottom:0;\n    right:0;\n"]))),Object(y.a)(O.a)(Z||(Z=Object(j.a)(["\n    font-size: 300%;\n"]))),Object(y.a)(b.a)($||($=Object(j.a)(["\n    // display: flex;\n    // flex-direction: row;\n    // background-color: red;\n    // align-items: center;\n    // border: 2px solid rgba(0,0,0,.125);\n    // box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    border: unset;\n"])))),le=(Object(y.a)(C.a)(_||(_=Object(j.a)(["\n    margin-right: 1%;\n"]))),Object(y.a)(v.a)(ee||(ee=Object(j.a)(["\n    justify-content: center;\n    margin-top: 9%;\n"])))),ue=Object(y.a)(ce.a)(ne||(ne=Object(j.a)(["\n    width: 100%;\n    display: flex;\n    flex-direction: column;\n    justify-content: space-around;\n"]))),ge=Object(y.a)(b.a.Header)(te||(te=Object(j.a)(["\n    justify-content: space-between;\n    display: flex;\n    align-items: center;\n    background-color: unset;\n    border-bottom: unset;\n"]))),he=Object(y.a)(de.a)(ie||(ie=Object(j.a)(["\n    width: 100%;\n    text-align: left;\n    position: relative;\n    padding: 2%;\n    margin-bottom: unset;\n"]))),xe=Object(y.a)(me.a)(oe||(oe=Object(j.a)(["\n    width: 100%;\n"])));var fe=function(e){Object(k.f)();var n,t=e.data,i=Object(k.g)(),o=i.drugtype,r=i.managementtype,a=T(T(t.drugs,[o]).gradeTypes,[r]).grades,s=Object(m.useState)(""),c=Object(ae.a)(s,2),d=c[0],p=c[1],l=Object(m.useState)(""),u=Object(ae.a)(l,2),g=u[0],h=u[1],x=[],f=Object(L.a)(a);try{var j=function(){var e=n.value;x.push(Object(q.jsx)(pe,{children:Object(q.jsxs)(se.a,{variant:"outline-primary",active:e.name===d,onClick:function(){return p(e.name)},children:[Object(q.jsxs)(ge,{children:[e.name,Object(q.jsx)(ce.a.Toggle,{as:se.a,variant:"",eventKey:e.name,children:"+"})]}),Object(q.jsx)(ce.a.Collapse,{eventKey:e.name,children:Object(q.jsx)(b.a.Body,{children:e.description})})]},"".concat(e.name," card"))}))};for(f.s();!(n=f.n()).done;)j()}catch(z){f.e(z)}finally{f.f()}var y=T(a,[d]),v=[];if(y&&y.followup){var O,C=Object(L.a)(y.followup.options);try{var I=function(){var e=O.value;v.push(Object(q.jsx)(se.a,{variant:"outline-primary",active:e.name===g,onClick:function(){return h(e.name)},children:e.name},"".concat(e.name," option")))};for(C.s();!(O=C.n()).done;)I()}catch(z){C.e(z)}finally{C.f()}}return Object(q.jsx)(q.Fragment,{children:Object(q.jsxs)(le,{children:[Object(q.jsx)(he,{variant:"dark",children:"Select Toxicity Grade:"}),Object(q.jsx)(ue,{children:x}),d&&(y.followup?Object(q.jsxs)(q.Fragment,{children:[Object(q.jsx)(he,{variant:"dark",children:y.followup.name}),Object(q.jsx)(xe,{children:v}),g&&Object(q.jsxs)(q.Fragment,{children:[Object(q.jsx)(he,{variant:"success",children:"Response:"}),Object(q.jsx)("div",{children:T(y.followup.options,[g]).response})]})]}):Object(q.jsx)("div",{children:y.response}))]})})},be=t(57);var je=function(){return Object(q.jsx)(V.a,{children:Object(q.jsx)(h.a,{fluid:!0,className:"App",children:Object(q.jsxs)(k.c,{children:[Object(q.jsx)(k.a,{path:"/toxicitymanagement/:drugtype/:managementtype/",render:function(e){return Object(q.jsx)(fe,Object(g.a)(Object(g.a)({},e),{},{data:be}))}}),Object(q.jsx)(k.a,{path:"/toxicitymanagement/:drugtype/",render:function(e){return Object(q.jsx)(re,Object(g.a)(Object(g.a)({},e),{},{data:be}))}}),Object(q.jsx)(k.a,{exact:!0,path:"/toxicitymanagement/",render:function(e){return Object(q.jsx)(U,Object(g.a)(Object(g.a)({},e),{},{data:be}))}}),Object(q.jsx)(k.a,{exact:!0,path:"/",component:J})]})})})},ye=function(e){e&&e instanceof Function&&t.e(3).then(t.bind(null,71)).then((function(n){var t=n.getCLS,i=n.getFID,o=n.getFCP,r=n.getLCP,a=n.getTTFB;t(e),i(e),o(e),r(e),a(e)}))};t(58);u.a.render(Object(q.jsx)(p.a.StrictMode,{children:Object(q.jsx)(je,{})}),document.getElementById("root")),ye()}},[[59,1,2]]]);
//# sourceMappingURL=main.a2542c1b.chunk.js.map